NUR 633 Module 6 Telehealth Paper Example

Monitoring Heart Failure at Home: What Three Trials Teach About Designing a Telemonitoring Program

[Student Name]

Southern New Hampshire University

NUR 633: Informatics and Communication Technology

Module Six Telehealth Paper

[Instructor Name]

[Date]

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

Monitoring Heart Failure at Home: What Three Trials Teach About Designing a Telemonitoring Program

Heart failure is a leading cause of hospital admission among older adults, and many readmissions follow a period of gradual fluid buildup that, in principle, could be caught early at home. Remote monitoring promises exactly that: daily weights and vital signs sent from the home, reviewed by clinicians, with treatment adjusted before the patient needs a hospital bed. Yet the evidence has been mixed, with some large trials showing no benefit. This paper compares three major trials to explain the mixed results and uses the explanation to design a telemonitoring program for a hospital heart failure clinic. It argues that telemonitoring works when the right patients are enrolled, the data are rich enough to act on and trained clinicians respond promptly, and that a program missing any of those elements should not be expected to succeed.

Two Trials That Found No Benefit

The Tele-HF trial randomized 1,653 patients recently hospitalized for heart failure to a telephone-based system, in which patients reported symptoms and weight daily through an interactive voice response system reviewed by site clinicians, or to usual care. After 180 days, readmission or death occurred in about half of each group, with no significant difference, and adherence to the daily calls fell substantially over time (Chaudhry et al., 2010). The BEAT-HF trial randomized 1,437 patients hospitalized for heart failure at six California academic centers to care transition support combining telephone coaching with telemonitoring of weight, blood pressure, heart rate and symptoms, or to usual care. It found no reduction in 180-day readmissions (Ong et al., 2016). Both trials relied on patients reporting data that nurses reviewed during working hours, and both saw adherence decline.

A Trial That Found Benefit

TIM-HF2 randomized 1,538 patients in Germany with heart failure, New York Heart Association class II or III symptoms and a heart failure hospitalization within the previous 12 months to remote patient management or usual care for one year. Patients used a weight scale, a blood pressure device, an electrocardiogram recorder and a pulse oximeter daily and rated their own health. The data went to a telemedical center staffed by physicians and nurses 24 hours a day, 7 days a week, which could contact the patient, adjust medications through the patient's physician or arrange admission. Its main endpoint counted the share of follow-up days a patient lost to an unplanned cardiac admission or to death. Remote management patients lost 4.88% of their days against 6.64% for the comparison group, and fewer of them died from any cause (Koehler et al., 2018).

Explaining the Difference

The three trials differ in ways that plausibly explain their results. First, enrollment: TIM-HF2 targeted patients with recent hospitalization and moderate symptoms, excluding those with severe depression, which may have selected patients able to engage and at enough risk to benefit. Second, data: TIM-HF2 collected objective physiologic measurements, including an electrocardiogram and oxygen saturation, rather than relying mainly on self-reported symptoms and weight. Third, response: TIM-HF2's center was staffed around the clock by clinicians with authority to act, while the US trials relied on site staff reviewing data during working hours. Fourth, context: TIM-HF2 was conducted within a health system where the center coordinated with patients' own physicians. The trials were not designed to test these factors separately, so the explanation is an inference, but it is consistent across the evidence and has clear implications for program design.

Program Design for Linden Park

Linden Park Hospital's heart failure clinic follows about 400 patients, and its 30-day readmission rate for heart failure is 21%. A program designed around the lessons above would include five elements. Enrollment: patients with heart failure and a hospitalization in the past 12 months, NYHA class II or III, who can use the devices with help from a family member if needed; patients with severe cognitive impairment or untreated depression would be screened and supported first. Data: daily weight, blood pressure, heart rate and a short symptom survey transmitted automatically through a cellular hub, with pulse oximetry for patients with lung disease. Response: a monitoring team of heart failure nurses covering 7 a.m. to 11 p.m. every day, with after-hours alerts routed to the on-call cardiology service, using standing protocols that allow nurses to adjust diuretic doses within defined limits and arrange same-day clinic visits. Integration: readings would flow into the electronic record so that clinic providers see trends at every visit. Support: device setup at discharge, a teach-back session and a technical support line.

Privacy, Equity and Adherence

Remote monitoring raises practical concerns. Devices and data transmission must meet security requirements, and because the monitoring vendor will handle patient information, a signed business associate contract is needed before launch. Patients without reliable internet can be served by cellular hubs, and loaner devices can address cost. Adherence is the most common weakness of telemonitoring, as Tele-HF showed when daily participation fell over the months; the program will track daily transmission rates and call patients who miss two consecutive days, treating missed readings as a clinical signal rather than a compliance failure.

Evaluation

The program will be evaluated over 12 months against a matched group of clinic patients not enrolled. Primary measures will be 30-day and 180-day heart failure readmissions and days alive and out of hospital. Process measures will include daily transmission rates, the time from an out-of-range reading to nurse contact and the proportion of alerts leading to a medication change. Patient experience and nurse workload will also be measured, since a program that overwhelms staff with alerts will not be sustained. Costs, including devices, monitoring staff and avoided admissions, will be reported to the finance committee at six and twelve months, because a program that reduces readmissions but cannot be funded beyond its first year helps no one in the long run.

Conclusion

Heart failure telemonitoring is not a single technology with a single effect. The negative US trials and the positive German trial suggest that benefit depends on enrolling patients at risk, collecting objective data and responding promptly with authority to act. A program at Linden Park built on those lessons, and honestly evaluated, has a reasonable chance of reducing readmissions; one that simply hands patients a scale would likely repeat the trials that failed.

References

Chaudhry, S. I., Mattera, J. A., Curtis, J. P., Spertus, J. A., Herrin, J., Lin, Z., Phillips, C. O., Hodshon, B. V., Cooper, L. S., & Krumholz, H. M. (2010). Telemonitoring in patients with heart failure. New England Journal of Medicine, 363(24), 2301-2309. https://doi.org/10.1056/NEJMoa1010029

Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B.-A., Winkler, S., Vettorazzi, E., Bruch, L., Oeff, M., Zugck, C., Doerr, G., Naegele, H., Stork, S., Butter, C., Sechtem, U., Angermann, C., Gola, G., Prondzinsky, R., . . . Stangl, K. (2018). Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): A randomised, controlled, parallel-group, unmasked trial. The Lancet, 392(10152), 1047-1057. https://doi.org/10.1016/S0140-6736(18)31880-4

Ong, M. K., Romano, P. S., Edgington, S., Aronow, H. U., Auerbach, A. D., Black, J. T., De Marco, T., Escarce, J. J., Evangelista, L. S., Hanna, B., Ganiats, T. G., Greenberg, B. H., Greenfield, S., Kaplan, S. H., Kimchi, A., Liu, H., Lombardo, D., Mangione, C. M., Sadeghi, B., . . . Fonarow, G. C. (2016). Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: The Better Effectiveness After Transition-Heart Failure (BEAT-HF) randomized clinical trial. JAMA Internal Medicine, 176(3), 310-318. https://doi.org/10.1001/jamainternmed.2015.7712